Home/Pipeline/SHR-1316

SHR-1316

Solid tumors

Phase 1/2Active

Key Facts

Indication

Solid tumors

Phase

Phase 1/2

Status

Active

Company

Jiangsu Hengrui Medicine

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd. is a leading Chinese pharmaceutical company founded in 1970, headquartered in Lianyungang, Jiangsu Province. The company has evolved from producing generic drugs to becoming a major innovator in oncology, with particular strength in developing novel cancer treatments, anesthesia drugs, and medical imaging contrast agents. Hengrui has established itself as one of China's most valuable pharmaceutical companies with significant R&D investments and an expanding global footprint.

View full company profile

Therapeutic Areas

Oncology Anesthesia Contrast Imaging Pain Management Hematology

Other Solid tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active
ONO-4538 combinations	Ono Pharmaceutical	Phase 2	Active